AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT00468546

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

A Phase 3 study testing MabThera/Rituxan and Methotrexate in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 115 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
MabThera/Rituxan and Methotrexate
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
520 participants
Where
115 sitesin 11 countries
Study dates
May 2003to Jul 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult participants 18-80 years of age with active RA for at least 6 months;
  • Received treatment for RA on an outpatient basis and experienced an inadequate response or intolerance to treatment with at least 1 anti-TNF alpha therapy (etanercept, infliximab or adalimumab);
  • Must have received MTX for a minimum of 12 weeks, with the last 4 weeks, prior to screening at a stable dose;
  • Participants with swollen joint count (SJC) and tender joint count (TJC) of at least 8 joints at screening and at randomization;
  • Radiographic evidence of at least 1 joint with a definite erosion due to RA;
  • Participants of reproductive potential must be using reliable contraceptive methods.

Who cannot join

  • Bone or joint surgery within 8 weeks prior to screening or joint surgery planned within 24 weeks of randomization;
  • Class IV functional status of RA;
  • Previous treatment within 6 months with intravenous gamma globulin, or the Prosorba column;
  • Intraarticular or parenteral corticosteroids within 4 weeks prior to screening visit;
  • With a live vaccine within 4 weeks prior to randomization;
  • Previous treatment with rituximab or other cell-depleting therapies;
Show all 19Show fewer
  • Concurrent treatment with any disease-modifying anti-rheumatic drug (except for MTX) or any anti-TNF alfa factor or other biologic therapy;
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies;
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders;
  • Known contraindications to receiving rituximab;
  • Known active bacterial, viral, fungal, mycobacterial or other infection;
  • History of recurrent significant infection or history of recurrent bacterial infections;
  • Primary or secondary immunodeficiency (history of, or currently active);
  • History of cancer, including solid tumors and hematologic malignancies (except basal cell or squamous cell carcinoma of the skin that have been excised and cured);
  • Women who are pregnant or breast-feeding;
  • History of alcohol, drug or chemical abuse within 6 months prior to screening;
  • Neuropathies and neurovasculopathies which might interfere with pain evaluation;
  • Participants with poor peripheral venous access;
  • Intolerance or contraindications to oral or intravenous corticosteroids.

Trial locations and contacts

115 sites in 11 countries.

115 sites in 11 countries

United States67 sites
  • Study site

    Albany, New York, 12206

  • Study site

    Amarillo, Texas, 79124

  • Study site

    Baltimore, Maryland, 21224

  • Study site

    Birmingham, Alabama, 35294

  • Study site

    Boca Raton, Florida, 33486

  • Study site

    Boise, Idaho, 83702

  • Study site

    Boston, Massachusetts, 02215

  • Study site

    Burlington, Vermont, 05401

  • Study site

    Chapel Hill, North Carolina, 27599-7600

  • Study site

    Chicago, Illinois, 60612

  • Study site

    Chicago, Illinois, 60637

  • Study site

    Cincinnati, Ohio, 45267-0563

  • Study site

    Cleveland, Ohio, 44195

  • Study site

    Coeur d'Alene, Idaho, 83814

  • Study site

    Dallas, Texas, 75231

  • Study site

    Dallas, Texas, 75246

  • Study site

    Danbury, Connecticut, 06810

  • Study site

    Dayton, Ohio, 45402

  • Study site

    Delray Beach, Florida, 33484

  • Study site

    Duncansville, Pennsylvania, 16635

  • Study site

    Durham, North Carolina, 27710

  • Study site

    Fort Lauderdale, Florida, 33334

  • Study site

    Fullerton, California, 92835

  • Study site

    Greenville, North Carolina, 27834

  • Study site

    Houston, Texas, 77074

  • Study site

    Indianapolis, Indiana, 46202-5149

  • Study site

    Indianapolis, Indiana, 46260

  • Study site

    Jupiter, Florida, 33458

  • Study site

    Kalamazoo, Michigan, 49048

  • Study site

    La Jolla, California, 92037

  • Study site

    Lansing, Michigan, 48910

  • Study site

    Largo, Florida, 33773

  • Study site

    Little Rock, Arkansas, 72205

  • Study site

    Los Angeles, California, 90045

  • Study site

    Los Angeles, California, 90048

  • Study site

    Madison, Wisconsin, 53717

  • Study site

    Madison, Wisconsin, 53792

  • Study site

    Manhasset, New York, 11030

  • Study site

    Mayfield, Ohio, 44143

  • Study site

    Meridian, Idaho, 83642

  • Study site

    Mesa, Arizona, 85208

  • Study site

    New York, New York, 10003

  • Study site

    Oklahoma City, Oklahoma, 73103

  • Study site

    Oklahoma City, Oklahoma, 73109

  • Study site

    Orlando, Florida, 32806

  • Study site

    Palo Alto, California, 94304

  • Study site

    Paradise Valley, Arizona, 85253

  • Study site

    Pasadena, California, 91105

  • Study site

    Philadelphia, Pennsylvania, 19140

  • Study site

    Philadelphia, Pennsylvania, 19141

  • Study site

    Philadelphia, Pennsylvania, 19152

  • Study site

    Rancho Mirage, California, 92270

  • Study site

    Rochester, Minnesota, 55905

  • Study site

    Rochester, New York, 14618

  • Study site

    Salt Lake City, Utah, 84132

  • Study site

    Santa Maria, California, 93454

  • Study site

    Seattle, Washington, 98101

  • Study site

    Seattle, Washington, 98104

  • Study site

    Shreverport, Louisiana, 71103

  • Study site

    Smithtown, New York, 11787

  • Study site

    Spokane, Washington, 99204

  • Study site

    St Louis, Missouri, 63110

  • Study site

    St Louis, Missouri, 63141

  • Study site

    Tucson, Arizona, 85724

  • Study site

    Tulsa, Oklahoma, 74135

  • Study site

    Upland, California, 91786

  • Study site

    Waco, Texas, 76708

Other trials in United States

Canada7 sites
  • Study site

    Calgary, Alberta, T2N 4Z6

  • Study site

    Edmonton, Alberta, T6G 2S2

  • Study site

    Hamilton, Ontario, L8N 2B6

  • Study site

    London, Ontario, N6A 4V2

  • Study site

    Toronto, Ontario, M4N 3M5

  • Study site

    Toronto, Ontario, M5G 1X5

  • Study site

    Vancouver, British Columbia, V5Z 1L7

Other trials in Canada

France7 sites
  • Study site

    Le Kremlin-Bicêtre, 94275

  • Study site

    Montpellier, 34295

  • Study site

    Paris, 75679

  • Study site

    Rouen, 76031

  • Study site

    Strasbourg, 67098

  • Study site

    Toulouse, 31059

  • Study site

    Tours, 37044

Other trials in France

Israel6 sites
  • Study site

    Haifa, 3109601

  • Study site

    Haifa, 3339419

  • Study site

    Jerusalem, 9112001

  • Study site

    Petah Tikva, 4941492

  • Study site

    Ramat Gan, 5262000

  • Study site

    Tel Aviv, 6423906

Other trials in Israel

Italy6 sites
  • Study site

    Arenzano, Liguria, 16011

  • Study site

    Brescia, Lombardy, 25123

  • Study site

    Genoa, Liguria, 16132

  • Study site

    Milan, Lombardy, 20157

  • Study site

    Pisa, Tuscany, 56100

  • Study site

    Udine, Friuli Venezia Giulia, 33100

Other trials in Italy

United Kingdom6 sites
  • Study site

    Cannock, WS11 5XY

  • Study site

    Leeds, LS7 4SA

  • Study site

    London, E11 1NR

  • Study site

    Manchester, M41 5SL

  • Study site

    Metropolitan Borough of Wirral, CH49 5PE

  • Study site

    Newcastle upon Tyne, NE7 7DN

Other trials in United Kingdom

Germany5 sites
  • Study site

    Berlin, 10117

  • Study site

    Dresden, 01067

  • Study site

    Leipzig, 04103

  • Study site

    Ratingen, 40882

  • Study site

    Würzburg, 97080

Other trials in Germany

Belgium4 sites
  • Study site

    Brussels, 1070

  • Study site

    Brussels, 1200

  • Study site

    Ghent, 9000

  • Study site

    Liège, 4000

Other trials in Belgium

Norway4 sites
  • Study site

    Drammen, 3004

  • Study site

    Lillehammer, 2609

  • Study site

    Oslo, 0370

  • Study site

    Tromsø, 9038

Other trials in Norway

Ireland2 sites
  • Study site

    Cork

  • Study site

    Dublin, 4

Other trials in Ireland

Netherlands1 site
  • Study site

    Amsterdam, 1105 AZ

Other trials in Netherlands

About this study

Official title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies

This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.

Being tested
MabThera/Rituxan, Methotrexate, Placebo
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00468546
Study groupRoleWhat they receive
Placebo Plus MethotrexatePlacebo comparatorParticipants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
Receives: Drug: Methotrexate; Other: Placebo
Rituximab plus MethotrexateExperimentalParticipants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
Receives: Drug: MabThera/Rituxan; Drug: Methotrexate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With American College of Rheumatology 20 Response at Week 24

    American College of Rheumatology (ACR) 20 response is defined as >= 20% improvement (reduction) in score compared with baseline for both tender joint count (TJC)-68 joints and swollen joint count (SJC)-66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) ranging from score 0 (no pain) to 100 (unbearable pain); Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging score 0 (no disease activity) to 100 (maximum disease activity); Health Assessment Questionnaire (HAQ):8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do) for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR).

    Measured: Week 24

Secondary outcomes (11)
  1. Number of Participants With an ACR 50 Response at Week 24

    ACR 50 response is defined as a >= 50% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.

    Measured: Week 24

  2. Number of Participants With ACR 70 Response at Week 24

    ACR 70 response is defined as a >= 70% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.

    Measured: Week 24

  3. Mean Change From Baseline in Disease Activity Score of 28 Joints at Week 24

    The disease activity score (DAS28) is an evaluation index of rheumatoid arthritis. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC-28 joints, 2. SJC -28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health (global health [GH]) status expressed by a VAS (0 [no disease activity] to 100 [maximum disease activity]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. Change from Baseline = difference between the score at Week 24 and the score at Baseline.

    Measured: From Baseline (Day 1) to Week 24

  4. Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission at Week 24

    The DAS28 is an evaluation index of RA. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC- 28 joints, 2. SJC- 28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health status (GH) expressed by a visual analogue scale VAS (0 [no disease activity] to 100 [maximum disease activity]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10. A participant was categorized as having low disease activity, if participant's DAS28 score was <= 3.2, and was categorized as having clinical remission if participant's DAS28 score was < 2.6.

    Measured: Week 24

  5. Number of Participants With Good, Moderate, or no European League Against Rheumatism Responses at Week 24

    European League Against Rheumatism (EULAR) response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. At a given visit, participants with a DAS28 score of < 3.2 are considered good responders if the change from baseline in their DAS28 score is >1.2. Participants with a DAS28 score >= 3.2 to 5.1 are considered moderate responders if the change from baseline in their DAS28 score is <=1.2 to >=0.6. Participants with DAS28 score >5.1 are considered non-responders if the change from baseline in their DAS28 score is <=1.2 to >=0.6.

    Measured: Week 24

  6. Percentage Change From Baseline in the ACR Core Set (SJC, TJC, Patient's and Physician's Global Assessments, Health Assessment Questionnaire, Pain, C-Reactive Protein, and Erythrocyte Sedimentation Rate) Score

    Percentage change in the scores of the following parameters of ACR core set relative to respective baseline scores in both study arms was analyzed : SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS [0 = no disease activity to 100 = maximum disease activity]), HAQ (based on HAQ disability index [HAQDI]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain), CRP concentration, and ESR.

    Measured: From Baseline (Day 1) to Week 24

  7. Mean Change From Baseline of Short Form 36 Total Scores at Week 24

    The Short Form (SF)-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Transforming and standardizing these domains leads to the calculation of the physical component summary and mental component summary measures. Scores on each item were summed and averaged (range 0 [worst] to 100 [best]); increase in score from baseline indicated improvement. Change from Baseline = difference between the score at Week 24 and the score at Baseline.

    Measured: From Baseline (Day 1) to Week 24

  8. Number of Participants With Categorical Change From Baseline in the Physical Component Scores of SF-36

    The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on physical component were summed and averaged (range 0 [worst] to 100 [best]); If participants' had shown change from baseline in physical health component score >5.42, it was considered as improved; score between -5.42 to 5.42 was considered as unchanged, and score < -5.42 was considered as worsened. Change from Baseline = difference between the score of physical component at Week 24 and the score at Baseline.

    Measured: From Baseline (Day 1) to Week 24

  9. Number of Participants With Change From Baseline in the Mental Component Scores of SF-36

    The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on mental component were summed and averaged (range = 0 [worst]-100 [best]); increase from baseline indicated improvement. If participants' had shown change from baseline in mental health score >6.33, it was considered as improved; scores between -6.33 to 6.33 was considered unchanged, and score <-6.33 was considered as worsened. Change from Baseline = difference between the mental component score at Week 24 and the score at Baseline.

    Measured: From Baseline (Day 1) to Week 24

  10. Mean Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score, Genant-modified Sharp Total Score, and Erosion Score

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290. For all the three radiograph assessment, the minimum score is 0. A higher score indicates more damage and a negative change score indicates improvement. The change in score is to be calculated as: Change from Baseline = difference between the score at Weeks 24, 56, or 104 and the score at Baseline.

    Measured: From Baseline (Day 1) to Weeks (W) 24, 56, and 104

  11. Percentage of Participants Without Erosive Progression

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage and negative change score indicates improvement.

    Measured: Up to Week 104

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2007 (estimated)
  2. Study startMay 2003
  3. Primary completionJan 2005
  4. Study completionJul 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
520 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00468546
Sponsor's protocol ID
WA17042
Other IDs
102-20
Status last verified
Aug 2016
First submitted
30 Apr 2007
Last updated
25 Oct 2016

Publications

  • Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596.

    PubMed 22127691
  • Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, Tak PP, Broder MS, Yu E, Cravets M, Magrini F, Jost F. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008 Jun 15;59(6):785-93. doi: 10.1002/art.23715.

    PubMed 18512710

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing MabThera/Rituxan and Methotrexate in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 115 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 115 sites in United States, Canada, France, Israel, Italy and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Oct 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With American College of Rheumatology 20 Response at Week 24 (time frame: Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00468546, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in